SUMMARY Prescription data for the three months before the last menstrual period and for the first trimester of pregnancy were obtained for 764 mothers whose children had a defect of the central nervous system and for an equal number of mothers of control babies born from the same doctors' practices. There was a statistically significant difference overall between the numbers of mothers who were prescribed drugs in the study and control groups during the trimester before the last menstrual period but no such difference was found for the first pregnancy trimester, nor was there a significant difference for any specific group of drugs. For a composite group of non-steroid anti-inflammatory drugs, salicylates, and sulphasalazine there was a significant difference for the trimester before the last menstrual period. There are arguments against such an artificial grouping, however, and when the individual drugs were considered the comparisons were no longer significant. The odds ratios for all medicines containing folic acid taken in the trimester before the last menstural period were considerably less than unity, in contrast with nearly all other comparisons. This supports a suggested protective effect against neural tube defects of folic acid supplements begun before the onset of pregnancy but the odds ratios of these comparisons were not statistically significant.
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In 1977 Greenberg and others' reported a study of the drug histories in the first trimester of pregnancy of 836 mothers of congenitally malformed children, 189 of whom had central nervous system defects, and an equal number of mothers of normal children. A positive association between the use of hormonal pregnancy tests and the subsequent birth of malformed children was found. Subsequent to this a further similar study on the mothers of congenitally malformed children and an equal number of mothers of normal children was undertaken by Cahal, Weatherall, and Adelstein (unpublished), covering the years 1976-80. Of 582 case-control pairs (183 central nervous sytem defects) studied, iron salts (with or without folic acid), anti-emetics, and antibiotics accounted for two thirds of all drugs prescribed in the first trimester. There was no evidence that they were teratogenic. There were significantly more prescriptions for bronchodilator drugs and for dextropropoxyphene in combination with paracetamol for the mothers of malformed children.
The present study was designed to cover notifications of central nervous system defects for one year, 1981. A total of 1078 notifications of actual or suspected defects were sent to the Committee on Safety of Medicines (CSM) by the Office of Population Censuses and Surveys (OPCS). These study children were paired with control children and analysis of maternal drug histories in the trimester (three calendar months) before the last menstrual period as well as in the first trimester of pregnancy was undertaken.
Patients and methods
The method of selection of patients and the study procedures were similar to those of the previous investigations. Each malformed (study) child was paired with a normal liveborn child without a congenital abnormality from the same medical practice. The control child was the nearest normal birth in the practice within three months after the birth of the study child, and if such a child was not available then the last normal child born within the practice before the birth of the study child was taken, provided that the interval did not exceed 12 months.
Method. Information on each study and control 1052 child and their mothers was obtained from the records of the family doctors, who were interviewed by part time medical officers (PTMOs) of the CSM. The children were not seen nor were their mothers interviewed. Data were collected on mother's age, family history, gestation period, outcome of the pregnancy, congenital abnormality in the study child, and drug prescriptions. Information on the drugs prescribed during the two study periods was obtained from the doctors' records only and is, therefore, not necessarily a complete record of drugs taken. It excluded hospital prescriptions, unless the doctors had a record of this, and also any Cover the counter' medicines which the mother might have taken. Gestation at any given date was calculated as the number of days or completed weeks from the first day of the last menstrual period. When the date of the last menstrual period was uncertain, obstetric and neonatal information was used to determine a probable date. This was done before analysing the results. The types of drug prescribed were recorded and where a drug had been prescribed more than once in either trimester it was noted as a single prescription in the appropriate trimester. Many of the medicines prescribed contained more than one active constituent. These constituents were analysed in terms of their therapeutic groups and may, therefore, be shown more than once in the analysis. In this study the risks of exposure to specific groups of drugs were calculated according to the method of Mantel and Haenszel2 for paired comparisons and then 95% confidence limits were estimated by the method of Breslow and Day.3
Results
Of the 1078 notifications of a central nervous system Table 4 gives an analysis of the number of mothers for whom drugs were prescribed. In the trimester before the last menstrual period there is a significant difference between the drugs prescribed for the study and control groups of mothers, more of the study mothers having been prescribed drugs than the controls; the odds ratio is 129 with 95% confidence limits of 1-19 to 1-42. In the first trimester of pregnancy no significant difference is found in drug prescribing between study and control mothers; the odds ratio being 0-88 with 95% confidence limits of 0-68 to 1-14.
Types of drugs prescribed. The main groups of drugs prescribed were iron salts, folic acid, antiemetics, antibiotics, and antihistamines. Other groups included central nervous system acting drugs, antifungal agents, oral contraceptives, infertility drugs, analgesics, and anticonvulsants. Tables 5 and 6 give details of these groups for each trimester. Oral contraceptives prescribed in either trimester were not associated with a significant effect, nor were infertility drugs.
It was noticeable that the folic acid groups in both trimesters showed lower odds ratios than any of the others, most of which were in excess of unity. The numbers of patients in the trimester before the last menstrual period were unavoidably small and the x2 values (X2 corrected for continuity) for the folic acid groups were not significant at the five per cent level. Six of seven control mothers had folic acid prescribed between 72 and five days before the last menstrual period, and for three the prescription was repeated in the first pregnancy trimester. The reasons for prescribing in the trimester before the last menstrual period were given as routine prophylaxis in two, prevention of anaemia in one, treatment of anaemia in one, iron deficiency in one, and iron treatment after a previous pregnancy in one as the preparations prescribed contained iron and folic acid. The remaining control mother was on continuous treatment for folic acid deficiency. A single study mother had folic acid prescribed six weeks before the last menstrual period for routine treatment after a previous normal pregnancy by a different partner. The father of the study child had two siblings both with central nervous system anomalies. Folic acid was not prescribed in the first pregnancy trimester.
In the first trimester, five study and eight control mothers had a folic acid preparation prescribed within four weeks of the last menstrual period, possibly as a prophylactic measure against central nervous system defects. In none of these mothers was there a history of previous children with a central nervous system defect. Two of the control mothers were also prescribed folic acid in the trimester before the last menstrual period, one for folic acid deficiency and the other as a prophylactic measure. Forty study mothers and 50 control mothers were prescribed folic acid between four and eight weeks from the last menstrual period, and 201 Four of 16 study mothers with a previously affected child were prescribed folic acid in the first trimester but none during the most sensitive period of organogenesis, (see Table 7 ). None of these study mothers was prescribed vitamins. One control mother had vitamins with folic acid at 11 weeks in the first trimester.
Only one of the nine study mothers prescribed vitamins without folic acid in the trimester before the last menstrual period was prescribed these because of a previous history of fetal malformations. The other eight mothers were prescribed vitamins (with or without iron salts), for menorrhagia in one and debility or pallor in the remainder. None of the six control mothers prescribed vitamins in the trimester before the last menstrual period was prescribed these as a prophylactic measure, the reasons being debility in five and abdominal discomfort in one.
In the present study iron-containing preparations were not significantly associated with the occurrence of central nervous system defects. Debendox was prescribed for 30 study and 29 control mothers in the first trimester.
Three of 764 study mothers had epilepsy, all three infants had spina bifida, and each mother had a different single anticonvulsant prescribed. None of the control mothers had suffered from epilepsy. One mother was prescribed sodium valproate in the first trimester only. Another mother had carbamazepine and the third phenytoin, each in both trimesters. One control mother was prescribed phenobarbitone for vomiting in early pregnancy.
Dextropropoxyphene with paracetamol was prescribed for nine study and two control mothers in the trimester before the last menstrual period, the odds ratio being 4-50, with 95% confidence limits of 44 On the basis that aspirin, non-steroidal antiinflammatory drugs, and sulphasalazine (an aminosalicylate) all have possibly similar anti-inflammatory activity, we produced a composite group of these drugs and found that they had been prescribed significantly more frequently for the study group of mothers during the trimester before the last menstrual period (odds ratio 2-14, 95% confidence limits 1-10 to 4-43, P=0-02). There are, however, arguments against combining these drugs in a single group. For instance, sulphasalazine is used to treat ulcerative colitis which might itself have a possible effect on the occurrence of fetal anomalies, although we are unaware of any. When these drug groups were evaluated separately, there were no significant differences in the odds ratios. In the first trimester no significant difference was shown for this compo-site group, the odds ratio being 1-67, with 95% confidence limits of 0-67 to 4-27.
Antibiotics, benzodiazepines, and tri-and tetracyclic antidepressants did not show any association with central nervous system defects when given in either trimester; neither did sympathomimetic drugs, bronchodilators, antispasmodics, etc.
Discussion
The mothers studied in this survey were not matched for age or for social class, and it would be presumptuous to suggest that every other possible confounding factor had been eliminated. Golding and colleagues4 comment that it is not technically possible to match for general practitioner as well as to match for social class and other factors in the mother which may be relevant.5 The mothers themselves were not interviewed to see what other drugs and medication they took during the two periods studied.
Some degree of inequality in the five year age subgroups has already been mentioned. Older women are said to have a greater tendency to give birth to malformed babies.5 There is also, however, a tendency for the rate to be increased for first births in the lower maternal age range in Britain.s Parity is also to some extent linked to age as regards this effect and may be an additional confounding factor. The design of this study was similar to that of the two studies already mentioned; neither age nor parity was a criterion for matching because of the method of selecting controls in which the infant rather than the mother was the determinant of inclusion in the control group. It is intended to carry out a further study in which an attempt to control for these factors as far as possible will be made. The results of this study must, therefore, be regarded to some extent as preliminary.
The proportion of stillbirths is lower than would be expected; this is largely due to the increasing numbers of central nervous system defects which are diagnosed antenatally and followed by termination of pregnancy. Weatherall6 showed a steady increase over the past ten years in the number of legal abortions carried out for medical reasons. In 1974 there were 2452 births and 34 terminations for central nervous system defects, in 1978 there were 1757 births and 194 terminations, and in 1981 the births notified totalled 1078 and there were 445 terminations. The rate of this decline in stillbirths seems to have accelerated but cannot be accounted for only by terminations. Central nervous system defects also seem to have declined in Northern Ireland,7 the United States,8 and Australia,"' though the reduction has been less striking in these countries than in England and Wales.
Nora and colleagues12 found an excess of children with central nervous system defects after maternal hormonal exposure, but our study did not show this. Three cohort studies (Robinson,'3 Royal College of General Practitioners Oral Contraception Study,'4 and Vessey and co-workers -') also provided no evidence of a significant association between oral contraceptive use and central nervous system defects, but the numbers of cases were small in these studies as in our present one. More recently, Cuckle and Wald'6 were unable to provide any further positive evidence on the oral contraceptives issue, adding that if a risk exists it can only be small. Infertility drugs were not associated with central nervous system malformations in our study, nor were they in the Collaborative Perinatal Project analysed by Heinonen et al. '7 Closure of the neural tube is usually considered complete by the fourth week of pregnancy so that if folic acid is to have a prophylactic effect against neural tube defects it is clearly necessary for it to have been taken before and immediately after conception. Our findings on folic acid, though not statistically significant, are not incompatible with those of recent studies'8 19 which show that folic acid supplementation before and during early pregnancy seems to reduce the risk of recurrence of neural tube defects in mothers who already have an affected child.
Mulinare and colleagues2" looked at the vitamin intake either preconceptually or during the first trimester, or both, among women who had offspring with a neural tube defect, their controls being women who had offspring with other malformations. A statistically significant protective effect of vitamin usage was shown for white mothers. The authors suggest that vitamins are usually begun in the latter part of the first trimester when their use could be in the stabilisation of cellular integrity of the neuropore after the 26th day of embryogenesis, with possible prevention of overdistension and subsequent rupture of the neuropore.
The above study did not, however, look at the role of folic acid separately from other vitamins and whether their influence was in either or both three month periods. Our analysis of vitamin prescribing, excluding folic acid, did not show any significance in either trimester.
Nelson and Forfar2' found that during the first 56 days of pregnancy a significantly high proportion of mothers of infants with major abnormalities took iron-containing preparations compared with control mothers, but no positive association was found in our study for either trimester. Aspirin alone did not show a significant effect in this study. Slone and others3' reporting on the Collaborative Perinatal Project on a cohort of 50 282 pregnant women of whom 64% took aspirin at some time during the pregnancy, concluded that the study gave no evidence that aspirin ingestion during pregnancy is associated with an increase in malformations. They also added that the data were so extensive that it was unlikely that any substantial teratogenic effect would have been missed. Anecdotal reports have implicated aspirin as a possible teratogen but there are also many instances of women taking large doses of aspirin throughout pregnancy without ill effects on the baby. Most of the evidence on aspirin suggests that it is not teratogenic if used in normal dosage.
The weakly positive finding for the antibiotics, benzodiazepines, and tri-and tetracyclic antidepressants for study mothers in the first trimester in the earlier report' could not be found in this present study. Two prescriptions only were given for barbiturates, and hormone pregnancy tests were not prescribed for any mother in our study. In the unpublished study by Cahal, Weatherall, and Adelstein significantly more bronchodilator drugs were prescribed to mothers of malformed children, however our study was not able to show this association. Many other groups of drugs were analysed but a positive association was not shown, (see Tables 5 and 6 ). Our findings for dextropropoxyphene in combination with paracetamol in the trimester before the last menstrual period, thyroid hormones in both trimesters, and anticonvulsants in the first trimester, though slightly suggestive, were not statistically significant.
We were impressed by the fact that the crude odds ratio was in excess of unity in the large majority of the comparisons, whereas for the preparations containing folic acid they were of the order 0-1, considerably lower than those for any other group. None of the ratios in excess of unity was statistically significant (with the exception of our combined non-steroid anti-inflammatory drug group in the trimester before the last menstrual period.) Although the confidence intervals for the folic acid preparations just reached unity, the low odds ratios could be regarded as possibly compatible with a protective effect of folic acid against neural tube defects, about which further data should be obtained from prospective studies.
The imperfections in study design to which we have referred are, we think, unlikely to have led to any major systematic bias. Our finding of a seemingly significant effect with regard to antiinflammatory drugs must be interpreted with considerable caution in view of the lack of any confirmatory experimental or clinical data, of the arguments against the aggregation of non-steroid anti-inflammatory drugs, salicylates, and sulphasalazine on which the validity of the significance depends, and of the absence of statistical significance when each member of the group is considered separately. Apart from this, we were unable to obtain any evidence of a teratogenic effect for any of the considerable number of drug groups examined.
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